Skip to main content
Erschienen in: Archives of Virology 8/2012

01.08.2012 | Original Article

In vitro and in vivo evaluation of a novel antiherpetic flavonoid, 4′-phenylflavone, and its synergistic actions with acyclovir

verfasst von: Kyoko Hayashi, Munekazu Iinuma, Kohei Sasaki, Toshimitsu Hayashi

Erschienen in: Archives of Virology | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

The development of therapeutic agents for preventing herpes simplex virus (HSV) infections has become urgently necessary because of the increasing incidence of this virus and its role as a cofactor in the transmission of human immunodeficiency virus infection. We have evaluated the antiviral activities of a series of natural and synthetic flavonoids and found that a synthetic flavonoid, 4′-phenylflavone, showed the highest activity against acyclovir (ACV)-sensitive and ACV-resistant strains of HSV-1, as well as HSV-2, with a selectivity index of 213, 35 and 55, respectively. Although the attachment and penetration of HSV-1 to host cells and the synthesis of viral proteins were not inhibited, the infectivity of the virus and the amount of progeny virus released were reduced by 4′-phenylflavone treatment in a dose-dependent manner. 4′-Phenylflavone plus ACV synergistically inhibited the replication of HSV-1. This flavonoid also showed efficacy in vivo and potentiated the antiherpetic effect of ACV in a mouse model of genital herpes. Our results suggest that 4′-phenylflavone might be useful as a candidate for the development of novel antiherpetic therapeutics.
Literatur
1.
Zurück zum Zitat Arvin AM, Prober CG (1997) Herpes simplex virus type 2—a persistent problem. N Engl J Med 337:1158–1159PubMedCrossRef Arvin AM, Prober CG (1997) Herpes simplex virus type 2—a persistent problem. N Engl J Med 337:1158–1159PubMedCrossRef
2.
Zurück zum Zitat Badam L, Joshi SP, Bedekar SS (1999) ‘In vitro’ antiviral activity of neem (Azadirachta indica. A. Juss) leaf extract against group B coxsackieviruses. J Communicable Dis 31:79–90 Badam L, Joshi SP, Bedekar SS (1999) ‘In vitro’ antiviral activity of neem (Azadirachta indica. A. Juss) leaf extract against group B coxsackieviruses. J Communicable Dis 31:79–90
3.
Zurück zum Zitat Cohen MS (1998) Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351:5–7PubMedCrossRef Cohen MS (1998) Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351:5–7PubMedCrossRef
4.
Zurück zum Zitat Corey L, Handfield HH (2000) Genital herpes and public health: addressing a global problem. JAMA 283:791–794PubMedCrossRef Corey L, Handfield HH (2000) Genital herpes and public health: addressing a global problem. JAMA 283:791–794PubMedCrossRef
5.
Zurück zum Zitat Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208:477–488PubMed Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208:477–488PubMed
6.
Zurück zum Zitat Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hyroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716–5720PubMedCrossRef Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hyroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716–5720PubMedCrossRef
7.
8.
Zurück zum Zitat Furman PA, St Clair MH, Fyfe LA, Rideout JL, Keller PM, Elion GB (1979) Inhibitiion of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol 32:72–77PubMed Furman PA, St Clair MH, Fyfe LA, Rideout JL, Keller PM, Elion GB (1979) Inhibitiion of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol 32:72–77PubMed
9.
Zurück zum Zitat Griffiths PA (1996) Herpesviruses and AIDS. Scand J Infect Dis Suppl 100:3–7PubMed Griffiths PA (1996) Herpesviruses and AIDS. Scand J Infect Dis Suppl 100:3–7PubMed
10.
Zurück zum Zitat Hayashi K, Hayashi T, Morita N (1992) Mechanism of action of the antiherpesvirus biflavone ginkgetin. Antimicrob Agents Chemother 36:1890–1893PubMedCrossRef Hayashi K, Hayashi T, Morita N (1992) Mechanism of action of the antiherpesvirus biflavone ginkgetin. Antimicrob Agents Chemother 36:1890–1893PubMedCrossRef
11.
Zurück zum Zitat Hayashi K, Hayashi T, Otsuka H, Takeda Y (1997) Antiviral activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. J Antimicrob Chemother 39:821–824PubMedCrossRef Hayashi K, Hayashi T, Otsuka H, Takeda Y (1997) Antiviral activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. J Antimicrob Chemother 39:821–824PubMedCrossRef
12.
Zurück zum Zitat Hayashi K, Kawahara K, Nakai C, Sankawa U, Seto H, Hayashi T (2000) Evaluation of (1R, 2R)-1-(5′-methyfur-3′-yl)propane-1,2,3-triol, a sphydrofuran derivative isolated from a Streptomyces species, as an anti-herpesvirus drug. J Antimicrob Chemother 46:181–189PubMedCrossRef Hayashi K, Kawahara K, Nakai C, Sankawa U, Seto H, Hayashi T (2000) Evaluation of (1R, 2R)-1-(5′-methyfur-3′-yl)propane-1,2,3-triol, a sphydrofuran derivative isolated from a Streptomyces species, as an anti-herpesvirus drug. J Antimicrob Chemother 46:181–189PubMedCrossRef
13.
Zurück zum Zitat Hofmann WP, Soriano V, Zeuzem S (2009) Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handbook Exp Pharmacol 189:321–346CrossRef Hofmann WP, Soriano V, Zeuzem S (2009) Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handbook Exp Pharmacol 189:321–346CrossRef
14.
Zurück zum Zitat Honess RW, Roizman B (1974) Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 14:8–19PubMed Honess RW, Roizman B (1974) Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 14:8–19PubMed
15.
Zurück zum Zitat Honess RW, Watson DH (1977) Herpes simplex virus resistance and sensitivity to phosphonoacetic acid. J Virol 21:584–600PubMed Honess RW, Watson DH (1977) Herpes simplex virus resistance and sensitivity to phosphonoacetic acid. J Virol 21:584–600PubMed
16.
Zurück zum Zitat Jabs DA, Enger C, Dunn JP, Forman M (1998) Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 177:770–773PubMedCrossRef Jabs DA, Enger C, Dunn JP, Forman M (1998) Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 177:770–773PubMedCrossRef
17.
Zurück zum Zitat Jancel T, Penzak SR (2009) Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Seminars Hematol 46:230–247CrossRef Jancel T, Penzak SR (2009) Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Seminars Hematol 46:230–247CrossRef
18.
Zurück zum Zitat Kaushic C, Ashkar AA, Reid LA, Rosenthal KL (2003) Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 77:4558–4565PubMedCrossRef Kaushic C, Ashkar AA, Reid LA, Rosenthal KL (2003) Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 77:4558–4565PubMedCrossRef
19.
Zurück zum Zitat Keller MJ, Klotman ME, Herold BC (2003) Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 49:279–284PubMedCrossRef Keller MJ, Klotman ME, Herold BC (2003) Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 49:279–284PubMedCrossRef
20.
Zurück zum Zitat Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L (1987) Recurrences after oral and genital herpes simplex virus infection. N Engl J Med 316:1444–1449PubMedCrossRef Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L (1987) Recurrences after oral and genital herpes simplex virus infection. N Engl J Med 316:1444–1449PubMedCrossRef
21.
Zurück zum Zitat Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 72:2760–2764PubMed Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 72:2760–2764PubMed
22.
Zurück zum Zitat Ljungman P (1996) Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 100:59–63PubMed Ljungman P (1996) Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 100:59–63PubMed
23.
Zurück zum Zitat Miller WH, Miller RL (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 31:3879–3884PubMedCrossRef Miller WH, Miller RL (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 31:3879–3884PubMedCrossRef
24.
Zurück zum Zitat Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A et al (1996) European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17:813–817PubMed Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A et al (1996) European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17:813–817PubMed
25.
Zurück zum Zitat Robin V, Iruzun A, Amoros M, Boustie J, Carrasco L (2001) Antipoliovirus flavonoids from Psiadia dentata. Antiviral Chem Chemother 12:283–291 Robin V, Iruzun A, Amoros M, Boustie J, Carrasco L (2001) Antipoliovirus flavonoids from Psiadia dentata. Antiviral Chem Chemother 12:283–291
26.
Zurück zum Zitat Sandoval IV, Carrasco L (1997) Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71:4679–4693PubMed Sandoval IV, Carrasco L (1997) Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71:4679–4693PubMed
27.
Zurück zum Zitat Serkedjieva J, Ivancheva S (1999) Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L. J Ethnopharmacol 64:59–68PubMedCrossRef Serkedjieva J, Ivancheva S (1999) Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L. J Ethnopharmacol 64:59–68PubMedCrossRef
28.
Zurück zum Zitat Talarico LB, Castilla V, Ramirez JA, Galagovsky LR, Wachsman MB (2006) Synergistic in vitro interactions between (22S, 23S)-3β-bromo-5α, 22, 23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemother 52:38–42CrossRef Talarico LB, Castilla V, Ramirez JA, Galagovsky LR, Wachsman MB (2006) Synergistic in vitro interactions between (22S, 23S)-3β-bromo-5α, 22, 23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemother 52:38–42CrossRef
29.
30.
Zurück zum Zitat Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seronegative persons: a meta-analysis. J Infect Dis 185:45–52PubMedCrossRef Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seronegative persons: a meta-analysis. J Infect Dis 185:45–52PubMedCrossRef
31.
Zurück zum Zitat Wilson SS, Fakioglu E, Herold BC (2009) Novel approaches in fighting herpes simplex virus infections. Expert Rev Antiinfective Ther 7:559–568CrossRef Wilson SS, Fakioglu E, Herold BC (2009) Novel approaches in fighting herpes simplex virus infections. Expert Rev Antiinfective Ther 7:559–568CrossRef
Metadaten
Titel
In vitro and in vivo evaluation of a novel antiherpetic flavonoid, 4′-phenylflavone, and its synergistic actions with acyclovir
verfasst von
Kyoko Hayashi
Munekazu Iinuma
Kohei Sasaki
Toshimitsu Hayashi
Publikationsdatum
01.08.2012
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 8/2012
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1335-6

Weitere Artikel der Ausgabe 8/2012

Archives of Virology 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.